EU OKs Celgene pancreatic cancer drug

|About: Celgene Corporation (CELG)|By:, SA News Editor

The European Commission has approved Celgene's (CELG) Abraxane treatment for metastatic pancreatic cancer when used in combination with the chemotherapy gemcitabine.

Abraxane is the first drug in seven years to be approved in Europe for the disease.

Celgene intends to start selling the therapy in the coming months according to local requirements. (PR)